Table 2.

Cell surface targets in AML currently under preclinical or clinical study

TargetMonoclonal antibodyADCBispecific antibodyCAR T Cell
CD7    X 
CD13 X  X  
CD33 X X1
NCT02724163 		X1
NCT05077423 		X1
NCT03971799 
CD38 X1
NCT03860844 		  X 
CD44v6 X   X 
CD47 X    
CD56  X  X 
CD70 X X  X 
CD74  X   
CD117  X   
CD123 X X1
NCT05320380 		X X1
NCT04318678, NCT04678336 
CD135 (FLT3)   X X1
NCT03904069 
Mesothelin  X X X 
Folate receptor α (FOLR1)  X2  X 
PRAME    X3 
WT1    X3 
HA-1    X1,3
NCT03326921 
NKG2DL    X 
IL1RAP    X 
CLL-1 (CLEC12A)  X X X 
TargetMonoclonal antibodyADCBispecific antibodyCAR T Cell
CD7    X 
CD13 X  X  
CD33 X X1
NCT02724163 		X1
NCT05077423 		X1
NCT03971799 
CD38 X1
NCT03860844 		  X 
CD44v6 X   X 
CD47 X    
CD56  X  X 
CD70 X X  X 
CD74  X   
CD117  X   
CD123 X X1
NCT05320380 		X X1
NCT04318678, NCT04678336 
CD135 (FLT3)   X X1
NCT03904069 
Mesothelin  X X X 
Folate receptor α (FOLR1)  X2  X 
PRAME    X3 
WT1    X3 
HA-1    X1,3
NCT03326921 
NKG2DL    X 
IL1RAP    X 
CLL-1 (CLEC12A)  X X X 
1

Indicates active pediatric trial with National Clinical Trials Network identifier provided.

2

Additional agent as C'dot drug conjugate.

3

T-cell receptor T cell.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal